Literature DB >> 3116916

Fleroxacin (Ro 23-6240) distribution in canine prostatic tissue and fluids.

T C Gasser1, P H Graversen, P O Madsen.   

Abstract

The distribution of fleroxacin (Ro 23-6240) in canine prostatic tissue and fluids was investigated under steady-state conditions during intravenous infusion. Mean ratios of fleroxacin concentration in tissue and fluids over concentration in plasma were 1.57 +/- 0.25 for prostatic tissue, 1.12 +/- 0.28 for prostatic secretion, and 0.93 +/- 0.14 for prostatic interstitial fluid. These levels and concentrations in urine were several times higher than the MIC for most pathogens that cause chronic bacterial prostatitis and urinary tract infection. The MICs for several isolates of Escherichia coli were only slightly affected by canine prostatic secretion, human prostatic tissue extract, and human urine. Clinical trials with fleroxacin appear justified for chronic bacterial prostatitis and urinary tract infection.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3116916      PMCID： PMC174862          DOI： 10.1128/AAC.31.7.1010

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  In vitro activity of Ro 23-6240, a new difluoroquinolone derivative, compared with that of other antimicrobial agents.

Authors:  N Manek; J M Andrews; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

2.  Bacteriologic localization patterns in bacterial prostatitis and urethritis.

Authors:  E M Meares; T A Stamey
Journal:  Invest Urol       Date:  1968-03

3.  Bactericidal intraprostatic concentrations of norfloxacin.

Authors:  M Bologna; L Vaggi; C M Forchetti; E Martini
Journal:  Lancet       Date:  1983-07-30       Impact factor: 79.321

4.  Duodeno-pancreatic secretions enhance bactericidal activity of antimicrobial drugs.

Authors:  H Mett; K Gyr; O Zak; K Vosbeck
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

5.  Intraprostatic concentration of ciprofloxacin and its activity against urinary pathogens.

Authors:  J A Hoogkamp-Korstanje; H J van Oort; J J Schipper; T van der Wal
Journal:  J Antimicrob Chemother       Date:  1984-12       Impact factor: 5.790

6.  Prostatitis syndromes: new perspectives about old woes.

Authors:  E M Meares
Journal:  J Urol       Date:  1980-02       Impact factor: 7.450

7.  The pH of prostatic fluid: a reappraisal and therapeutic implications.

Authors:  W R Fair; J J Cordonnier
Journal:  J Urol       Date:  1978-12       Impact factor: 7.450

8.  Diffusion of ciprofloxacin into prostatic fluid.

Authors:  A Dalhoff; W Weidner
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

9.  Experimental models for determination of antimicrobials in prostatic tissue, interstitial fluid and secretion.

Authors:  P O Madsen; A Baumueller; U Hoyme
Journal:  Scand J Infect Dis Suppl       Date:  1978

10.  Rosoxacin and cinoxacin distribution in prostate, vagina, and female urethra. An experimental study in dogs.

Authors:  S Maigaard; N Frimodt-Möller; U Hoyme; P O Madsen
Journal:  Invest Urol       Date:  1979-09
View more
  6 in total

Review 1.  The role of quinolones in the treatment of chronic bacterial prostatitis.

Authors:  K G Naber
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Timing, dosing and duration of antimicrobial prophylaxis in urology: a study in guinea pigs with special reference to high-risk conditions.

Authors:  T C Gasser; P O Madsen
Journal:  Infection       Date:  1993 Jan-Feb       Impact factor: 3.553

Review 3.  Quinolones in urology.

Authors:  K T Nielsen; P O Madsen
Journal:  Urol Res       Date:  1989

4.  Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.

Authors:  A J Fischman; E Livni; J W Babich; N M Alpert; A Bonab; S Chodosh; F McGovern; P Kamitsuka; Y Y Liu; R Cleeland; B L Prosser; J A Correia; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

5.  Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; J A Correia; H W Strauss
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

6.  Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; R J Callahan; J A Correia
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.